Transarterial Ethanol Ablation for Unresectable Hepatocellular Carcinoma: Analysis of Clinical and Tumor Outcomes  by Yu, Simon Chun Ho et al.
CLINICAL STUDYTransarterial Ethanol Ablation for Unresectable
Hepatocellular Carcinoma: Analysis of
Clinical and Tumor Outcomes
Simon Chun Ho Yu, MD, Edwin Pun Hui, FRCP, Peggy Tang, FRCR,
Stephen Ka Chi Chan, FRCR, Charmant Cheuk Man Chu, FRCR,
Joyce Wai Yi Hui, FRCR, Stephen Lam Chan, FRCP, Kit Fai Lee, FRCS,
Paul Bo San Lai, MD, and Winnie Yeo, MDABSTRACT
Purpose: To evaluate survival, tumor response, and treatment toxicity of transarterial ethanol ablation (TEA) in patients with
unresectable hepatocellular carcinoma (HCC).
Materials and Methods: This prospective study involved 186 patients (146 men and 40 women; median age, 65 y [interquartile
range, 57–72.3 y]). Of 186 patients, 146 (78.5%) were hepatitis B virus carriers, 18 (9.7%) were hepatitis C virus carriers, 82
(44.1%) had tumorsZ 5 cm, and 43 (23.1%) had multifocal tumors. Overall survival (OS), complete response (CR) by European
Association for the Study of the Liver criteria, time to progression (TTP), progression-free survival (PFS), and treatment
toxicities were evaluated. Univariate and multivariate analyses for prognostic factors of OS were performed.
Results: Median OS was 25.7 months (95% conﬁdence interval [CI], 20.9–30.5) and varied signiﬁcantly between Child-Pugh A
and B (28.7 mo vs 13.4 mo, P o .001), and Barcelona Clinic Liver Cancer A and B or C (37.1 mo vs 17.7 mo, P ¼ .001).
Prognostic factors for longer OS were solitary tumor, tumor size o 5 cm, 4 1 treatments, and CR of all tumors at 6 months.
TTP was 9.1 months (95% CI, 6.9–11.3). PFS was 8.4 months (95% CI, 7.1–9.7). CR occurred in 69.1% (159/230) of lesions and
48.9% (88/180) of patients at 6 months. Any one symptom of the postembolization syndrome of grade 2 severity occurred ino
22% (41/186) of patients. No treatment-related hepatitis or death occurred within 30 days. Transient respiratory decompensation
occurred in three patients (1.6% [3/186]), and alcoholic intoxication occurred in one patient (0.5% [1/186]).
Conclusions: TEA appears to be safe and effective for local control of HCC.
ABBREVIATIONS
CI = conﬁdence interval, CR = complete response, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, IQR = interquartile
range, LEM = Lipiodol and ethanol mixture, OS = overall survival, PFS = progression-free survival, TEA = transarterial ethanol
ablation, TTP = time to progression& SIR, 2016. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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spondence to S.C.H.Y.; E-mail: simonyu@cuhk.edu.hkTransarterial ethanol ablation (TEA) has been intro-
duced for the treatment of hepatocellular carcinoma
(HCC) (1–3), which is one of the most common solid
malignancies globally (4). In a recent randomized
controlled trial comparing transcatheter arterial chemo-
embolization and TEA, TEA was found to be associated
with a signiﬁcantly higher complete tumor response rate,
longer time to intralesional progression, and longer
survival free from intralesional progression (3). In
TEA, an ablative agent of ethiodized oil (Lipiodol)
and ethanol mixed in a 2:1 ratio by volume (LEM) is
used (Lipiodol Ultra-Fluide; Guerbet, Villepinte, France,
and dehydrated alcohol [absolute alcohol]; Martindale
Pharma, Buckinghamshire, United Kingdom). In ani-
mal experiments, TEA was effective in permeating the
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cirrhotic livers (5,6), producing long-lasting occlusion of
the arterioles and portal venules, leading to infarction of
the affected liver tissue (6). Because TEA is potentially a
promising treatment for HCC, knowledge of the factors
affecting treatment outcomes would be clinically valuable
in guiding patient selection, and knowledge of tumor
response after treatment and treatment toxicity would
allow better understanding of the limits and risks of its
clinical application. The objective of this study was to
evaluate the survival, tumor response, and treatment
toxicity of TEA in patients with unresectable HCC.MATERIALS AND METHODS
Study Design
This prospective study was conducted in accordance
with the Declaration of Helsinki and international
standards of Good Clinical Practice and was approved
by our institutional review board. A signed informed
consent was obtained from all patients. Patient recruit-
ment took place between July 2001 and April 2011. The
patients were followed until death or the date of analysis
in June 2013. The primary endpoint was overall survival
(OS). Secondary endpoints were time to progression
(TTP), progression-free survival (PFS), tumor response,
and treatment-related toxicity.
Eligibility Criteria for Participants
Recruitment occurred in a joint clinic comprising oncol-
ogists, surgeons, and radiologists. TEA was indicated for
patients with intrahepatic HCC that was not amenable
to partial hepatectomy or liver transplantation because
of patient refusal, suboptimal liver function, or tumor
condition not meeting the criteria required for these
surgical interventions. The study was carried out in a
period when radiofrequency ablation (for tumor r 3
cm), transcatheter arterial chemoembolization, and
radioembolization were the mainstays of treatment for
unresectable HCC in our institution. The number of
patients treated with radiofrequency ablation, transcath-
eter arterial chemoembolization, radioembolization, and
TEA were 163, 596, 68, and 186. Selection criteria for
TEA were (i) massive expansive tumor morphology with
a measurable lesion on computed tomography (CT) or
magnetic resonance (MR) imaging, characterized by
well-deﬁned spherical or globular conﬁguration; (ii)
hypervascularity of lesions as evaluated on triphasic
CT or MR imaging; and (iii) ﬁve or fewer tumors.
Transcatheter arterial chemoembolization or radioem-
bolization was the treatment modality in patients with
the following tumor characteristics: (i) inﬁltrative tumor
morphology, characterized by ill-deﬁned tumor margin
and amorphous conﬁguration; (ii) diffuse tumor mor-
phology, characterized by a large number of small
nodules; and (ii) more than ﬁve tumors. Patients withtumor invasion of the main trunk or a lobar branch of
portal vein were treated with radioembolization. Addi-
tional eligibility criteria were required for patient recruit-
ment into the study. Inclusion criteria included patient
consent; age4 18 years old; Child-Pugh classiﬁcation A
or B cirrhosis; Eastern Cooperative Oncology Group
performance score r 2; absence of serious concurrent
medical illness; histologically or cytologically proven
HCC, liver masses with typical features of HCC on
CT or MR imaging, or liver masses associated with α-
fetoprotein level4 200 ng/mL; massive expansive tumor
morphology with measurable lesions on CT; total tumor
mass o 50% liver volume; and ﬁve or fewer tumors.
Exclusion criteria included serum creatinine level 4 180
μmol/L, biliary obstruction not amenable to percuta-
neous drainage, Child-Pugh C cirrhosis, serum total
bilirubin level Z 50 μmol/L, serum albumin level o 25
g/L, international normalized ratio 4 1.5, inﬁltrative or
diffuse tumor morphology, extrahepatic metastasis,
tumor invasion of the main trunk or lobar branch of
portal vein, tumor invasion of hepatic vein, signiﬁcant
arterioportal venous shunt affecting more than one
hepatic segment on CT, and signiﬁcant arteriovenous
shunt with hepatic vein opaciﬁed in arterial phase on
CT. The status of liver cirrhosis was assessed at baseline
with ultrasound or CT. The ultrasound criteria we used
for diagnosing cirrhosis included coarse granularity of
the texture of liver parenchyma, nodularity at the liver
surface, or blunting of the liver edge. CT criteria
included nodularity at the liver surface or blunting of
the liver edge.Patient Demographics
There were 186 patients, including 146 men (78.5%) and
40 women (21.5%), with a median age of 65 years
(interquartile range [IQR], 57–72.3 y), enrolled in the
study and treated with TEA. No one was lost to follow-
up until death or the date of analysis. Of 186 patients,
184 patients (98.9%) had an Eastern Cooperative Oncol-
ogy Group performance score r 1, 146 (78.5%) were
hepatitis B virus (HBV) carriers, 18 (9.7%) were hepatitis
C virus carriers, 151 (81.2%) had ultrasound or CT
evidence of cirrhosis, 82 (44.1%) had tumors Z 5 cm,
and 43 (23.1%) had multifocal tumors. There were 65
(34.9%) patients who had received other treatments
before enrollment, including liver resection in 27
(14.5%) patients, microwave ablation or radiofrequency
ablation in 16 (8.6%) patients, transcatheter arterial
chemoembolization using cisplatin and gelatin sponge
in 19 (10.2%) patients, and radioembolization using
yttrium-90 in 3 (1.6%) patients. These prior treatments
were administered at a median of 24.2 months (95%
conﬁdence interval [CI], 10.7–58.3) before enrollment.
The tumors were solitary in 143 patients (76.9%),
occupied r 50% of the liver in 163 patients (87.6%),
had mean diameter 5.6 cm  3.5, and had mean volume
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portal vein was present in seven (3.8%) patients
(Table 1).
Treatment Procedures
All procedures were performed by an interventional
radiologist who had 5 years of experience in transarterial
treatments for HCC at the start of the study (S.C.H.Y.).
The arteries supplying the tumors were identiﬁed with
digital subtraction angiography and selectively catheter-
ized using a microcatheter (FasTracker-18MX infusion
catheter; Boston Scientiﬁc Target Therapeutics, Fre-
mont, California). The tip of the microcatheters was
placed as close to the tumor as possible, with an aim to
deliver LEM to ﬁll up the whole tumor vasculature of all
tumors completely under ﬂuoroscopic control until there
was intraarterial ﬂow stasis or ﬁlling of segmental portal
branches. For large tumors that occupied the whole liver
lobe, lobar infusion of LEM through the lobar artery
was performed until there was ﬁlling of portal branches
or when the maximum dose of 60 mL per treatment
session was reached (1,2). For prophylactic pain control,
intraarterial lidocaine 1% (Xylocaine 1%; AstraZeneca
Pty Ltd, Sydney, Australia) up to 5 mL per treatment
session was given intraarterially just before LEM deliv-
ery (1–3). Patients underwent further treatment sessions
when there was CT evidence of residual tumors or new
hepatic tumors on 3-monthly follow-up CT scanning.
TEA was not administered when the patient developed
intrahepatic disease progression unresponsive to TEA,
vascular invasion, extrahepatic metastasis, or deteriora-
tion in liver function. These patients (n = 18) were
treated with sorafenib (Bayer AG, Leverkusen, Ger-
many) after 2009 if there was no contraindication for
sorafenib. In 146 patients with HBV, 76 patients (52.1%)
were treated with antiviral therapy after February 2003
using lamivudine (GlaxoSmithKline, London, United
Kingdom), entecavir (Bristol-Myers Squibb, New York,
New York), or adefovir (Gilead Sciences, Foster City,
California).
Assessment of Clinical Outcome and
Tumor Response
OS was deﬁned as time from ﬁrst treatment of TEA to
death from any cause. Patients who underwent liver
resection or liver transplantation after treatment or were
alive at the time of analysis were censored. Patients were
followed at 2-month intervals at the clinic until death or
time of analysis. Blood tests for serum α-fetoprotein level
and liver function were performed. Patients were also
followed with triphasic contrast-enhanced CT at baseline
and at 3-month intervals after the commencement of the
ﬁrst treatment session until liver resection, disease pro-
gression, or death. Multiplanar CT was performed with
100 mL iohexol (Omnipaque 300; Amersham Health,
Cork, Ireland) administered intravenously at 2.5 mL/sand triphasic CT scanning (LightSpeed VCT 16 or 64 or
64 XT; GE Healthcare, Wauwatosa, Wisconsin) ac-
quired at 30 seconds, 70 seconds, and 5 minutes. All
CT images were interpreted by two groups of two
radiologists who had 4–8 years of experience in HCC
imaging. Treatment responses of individual treated
tumor lesions on CT were classiﬁed at the time of
analysis according to the European Association for the
Study of the Liver criteria (7–9). Tumor response was
classiﬁed into four categories: (i) complete response
(CR), (ii) partial response, (iii) static disease, or (iv)
disease progression. Disease progression was subclassi-
ﬁed into three categories: (i) intralesional progression,
(ii) intrahepatic-extralesional progression, or (iii) extra-
hepatic progression. These three conditions were eval-
uated in retrospect at the time when they were ﬁrst
detected. Discrepancy in the classiﬁcation of tumor
response between the two groups of radiologists was
resolved by consensus. Overall tumor response of an
individual patient was classiﬁed as CR only when there
was CR in all lesions of that patient; it was classiﬁed as
partial response, static disease, or disease progression
when there was partial response, static disease, or disease
progression in any one of the lesions in that patient.
When partial response, static disease, and disease pro-
gression occurred together in different lesions of the
same patient, the overall response was classiﬁed accord-
ing to the worst class of response in that patient.
Treatment-Related Adverse Events
Clinical and laboratory data were documented prospec-
tively at baseline; during hospitalization; and at 7, 14,
and 30 days and 2 months. Laboratory ﬁndings were
graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events
Version 2.0. Treatment-related hepatitis was diagnosed
when the plasma level of alanine aminotransferase
exceeds three times the upper limit of normal.
Statistical Analyses
Statistical calculation was performed with IBM SPSS
Statistics for Windows version 20 (IBM Corporation,
Armonk, New York). OS was calculated with the
Kaplan-Meier method. Median OS was deﬁned as the
time when half of the individuals experienced the events.
Factors affecting OS were analyzed with univariate and
multivariate analysis using the Cox regression model.
Subgroup analyses of OS according to Child-Pugh
cirrhosis classiﬁcation, Barcelona Clinic Liver Cancer
staging classiﬁcation, and United Network for Organ
Sharing staging classiﬁcation were performed using log-
rank test and demonstrated with Kaplan-Meier curves.
The median OS of patients treated with sorafenib was
compared with median OS of patients without sorafenib
treatment using log-rank test. The median OS of patients
with HBV treated with antiviral therapy was compared
Table 1 . Patient Demographics and Tumor Characteristics
Characteristics
(N ¼ 186 patients) No. patients (%)
Age (y)
Mean  SD 64.1  11.2
Median (IQR) 65 (57–72.3)
Sex
Male 146 (78.5)
Female 40 (21.5)
Etiology
Cryptogenic 22 (11.8)
Hepatitis B virus 146 (78.5)
Hepatitis C virus 18 (9.7)
Diagnosis
Biopsy-conﬁrmed HCC 101 (54.3)
Imaging  AFP 85 (45.7)
ECOG performance status
0 179 (96.2)
1 5 (2.7)
2 2 (1.1)
Child-Pugh classiﬁcation
A 159 (85.5)
B 27 (14.5)
Cirrhosis by imaging
Absent 35 (18.8)
Present 151 (81.2)
Ascites
Absent 162 (87.1)
Present 24 (12.9)
Prior therapy
None 121 (65.1)
Liver resection 27 (14.5)
Microwave or
radiofrequency ablation
16 (8.6)
Chemoembolization 19 (10.2)
Radioembolization 3 (1.6)
AFP level (ng/mL) Median 64, range 1–106,335
r 400 131 (70.4)
4 400 55 (29.6)
Platelet count (109/L) Median 123, range 21–399
Grade 0 (4 140) 74 (39.8)
Grade 1 (76–140) 67 (36)
Grade 2 (51–75) 25 (13.4)
Grade 3 (10–50) 20 (10.8)
Prothrombin time (s) Median 11.5, range 9.2–17.7
o 10 16 (8.6)
10–13 135 (72.6)
4 13 35 (18.8)
INR Median 1.2, range 0.9–1.7
r 1.2 129 (69.4)
4 1.2 57 (30.6)
Albumin (g/L) Median 37, range 23–48
Grade 0 (4 35) 117 (62.9)
Grade 1 (30–35) 52 (28)
Grade 2 (20–29) 17 (9.1)
Total bilirubin (μmol/L) Median 13, range 4–47
Grade 0 (r 17) 121 (65.1)
Continued
Table 1. Patient Demographics and Tumor
Characteristics (continued)
Characteristics
(N ¼ 186 patients) No. patients (%)
Grade 1 (18–25.5) 35 (18.8)
Grade 2 (26–51) 30 (16.1)
Tumor number
Solitary 143 (76.9)
Multifocal 43 (23.1)
Largest tumor size (cm) Median 4.4, range 1–19.3
o 5 104 (55.9)
5–10 60 (32.3)
4 10 22 (11.8)
Tumor distribution
Bilobar 21 (11.3)
Unilobar 165 (88.7)
Tumor burden (%)
r 50 163 (87.6)
4 50 23 (12.4)
Venous invasion or
extrahepatic metastasis
Absent 177 (95.2)
Portal vein invasion 7 (3.8)
Extrahepatic invasion 2 (1.1)
BCLC staging classiﬁcation
A Single tumorr 5 cm, oro
3 noduleso 3 cm, PST ¼ 0,
Child-Pugh A or B
89 (47.9)
B Single tumor4 5 cm, orZ
3 nodules, PST ¼ 0, Child-
Pugh A or B
88 (47.3)
C Portal invasion, N1, M1, PST
¼ 1–2, Child-Pugh A or B
9 (4.8)
UNOS staging classiﬁcation
T1 (1 tumor o 2 cm) 11 (5.9)
T2 (1 tumor r 5 cm, 2 or 3
tumors with largest 1 r 3
cm
80 (43)
T3 (1 tumor 4 5 cm, 2 or 3
tumors with at least 1 4 3
cm)
84 (45.2)
T4a (Z 4 tumors) 2 (1.1)
T4b (RPV/LPV invasion) 7 (3.8)
N (lymph node 4 2 cm)
M (MPV invasion/
extrahepatic metastasis)
2 (1.1)
Sorafenib
No 168 (90.3)
Yes 18 (9.7)
Antiviral therapy (146 patients
with HBV)
No 70 (47.9)
Yes 76 (52.1)
AFP ¼ α-fetoprotein; BCLC ¼ Barcelona Clinic Liver Cancer; ECOG
¼ Eastern Cooperative Oncology Group; HBV ¼ hepa-
titis B virus; HCC ¼ hepatocellular carcinoma; INR ¼ international
normalized ratio; IQR ¼ interquartile range; LPV ¼ left portal vein;
MPV ¼ main portal vein; PST ¼ performance status test; RPV ¼
right portal vein; UNOS ¼ United Network for Organ Sharing.
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using log-rank test. TTP and PFS were calculated using
the Kaplan-Meier method. TTP and PFS regarding
intrahepatic-extralesional progression or extrahepatic
progression in patients with HBV treated with antiviral
therapy were compared with TTP and PFS of patients
without antiviral therapy using log-rank test.RESULTS
TEA was completed in all patients. Each patient
received a median of two treatments (95% CI, 1–4). A
mean LEM dose of 19.0 mL  19.6 (median, 10 mL;
IQR, 4.5–28.5 mL) was given in the ﬁrst treatment.Clinical Outcome
The median OS was 25.7 months (95% CI, 20.9–30.5).
Median TTP was 9.1 months (95% CI, 6.9–11.3).
Median PFS was 8.4 months (95% CI, 7.1–9.7). Factors
associated with a signiﬁcantly longer OS in multivariate
analysis were solitary tumor (median OS 29.7 mo vs 19.7
mo, P = .034), tumor diametero 5 cm (median OS 30.9
mo vs 19 mo, P = .026), more than one TEA treatment
(median OS 29.1 mo vs 16.8 mo, P = .019), and CR of
all tumors at 6 months (median OS 35.9 mo vs 17.7 mo,
Po .001) (Table 2). Other factors that were found to be
associated with a signiﬁcantly longer OS on Kaplan-
Meier analysis included Child-Pugh A versus Child-
Pugh B cirrhosis (median OS 28.7 mo vs 13.4 mo, P
o .001) (Fig 1), Barcelona Clinic Liver Cancer stage A
versus Barcelona Clinic Liver Cancer stage B or C
(median OS 37.1 mo vs 17.7 mo, P ¼ .001) (Fig 2),
and United Network for Organ Sharing stage T1 or T2
versus United Network for Organ Sharing T3 or others
(median OS 36.1 mo vs 19.0 mo, P ¼ .003) (Fig 3). The
median OS of patients with tumor in a segmental portal
venous branch and patients without tumor in a
segmental portal venous branch was 33.5 months
(IQR, 2.1–64.8 mo) and 25.7 months (IQR, 20.4–30.9
mo), respectively. The difference was not statistically
signiﬁcant (P ¼ .797). The median OS of patients who
received sorafenib and patients who did not receive
sorafenib was 27.7 months (IQR, 13.7–41.7 mo) and
25.7 months (IQR, 20.4–30.9 mo), respectively. The
difference was not statistically signiﬁcant (P ¼ .765).
Compared with patients without antiviral therapy,
patients with HBV treated with antiviral therapy had
signiﬁcantly longer median OS (34.6 mo vs 16.8 mo,
P ¼ .002), signiﬁcantly longer median PFS regarding
intrahepatic-extralesional progression or extrahepatic
progression (11.7 mo vs 8 mo, P ¼ .023), and longer
median TTP regarding intrahepatic-extralesional pro-
gression or extrahepatic progression, although the differ-
ence was not statistically signiﬁcant (11.9 mo vs 8.5 mo,
P ¼ .345).Treatment Response
CR of individual tumor lesions occurred in 69.1% (170
of 246) of lesions at 3 months and 69.1% (159 of 230) at
6 months (Figs 4a–e, 5a–d). Intralesional disease
progression occurred in 4.1% (10 of 246) of lesions at 3
months and 10.4% (24 of 230) at 6 months. Regarding
overall tumor response of individual patients, CR
occurred in 60.2% (112 of 186) of patients at 3 months
and 48.9% (88 of 180) at 6 months. Intralesional disease
progression occurred in 5.4% (10 of 186) of patients at 3
months and 12.2% (22 of 180) at 6 months. Intrahepatic-
extralesional or extrahepatic disease progression
occurred in 9.1% (17 of 186) of patients at 3 months
and 26.7% (48 of 180) at 6 months (Table 3).
Treatment-Related Adverse Events
Fever, abdominal pain, or vomiting after embolization
was usually of grade 1 or 2 in severity. In 186 patients,
fever of grade 1 and 2 severity occurred in 87 (46.8%)
patients and 41 (22%) patients, respectively. Grade 1 and
2 abdominal pain occurred in 87 (46.8%) patients and 27
(14.5%) patients, respectively. Grade 3 abdominal pain
was rare and occurred in three (1.6%) patients. Vomiting
and fatigue of grade 1 or 2 severity occurred in 23
(12.4%) patients and 47 (25.3%) patients, respectively
(Table 4). Derangement in one of the liver function
parameters with severity grade 3 or greater was
uncommon, occurring in six (3.2%) patients, seven
(3.7%) patients, 14 (6.4%) patients, and 10 (5.4%)
patients at baseline, 2 weeks, 1 month, and 2 months.
There was no evidence of treatment-related hepatitis.
Transient respiratory decompensation occurred in three
(1.6%) patients; the condition was associated with
relatively large tumors (6.2 cm, 13 cm, and 14 cm) that
had been treated with a relatively large dose of LEM (36
mL, 60 mL, and 60 mL). The patients presented acutely
with oxygen desaturation and shortness of breath. Chest
radiograph showed miliary pulmonary shadows on the
same day and small pleural effusion afterward. The
radiographic signs subsided completely in 1 week. The
patients recovered completely within 10 days after treat-
ment with oxygen and steroid. Alcohol intoxication
manifesting with transient confusion and drowsiness
occurred in 1 (0.5%) patient (Table 4).DISCUSSION
The treatment goal of locoregional therapy is to achieve
CR of the treated lesions and ultimately to prolong
patient survival. The superiority of TEA over trans-
catheter arterial chemoembolization in achieving CR for
HCC lesions was suggested in a case-control study and a
randomized controlled trial (1,3). The CR rate by
European Association for the Study of the Liver criteria
on a tumor basis was signiﬁcantly higher in the TEA
arm at 6 months (72.2% vs 53.9%, P = .012) (3). In the
Table 2 . Univariate and Multivariate Analysis for Factors Affecting Overall Survival
Category
(No. Patients)
Kaplan-Meier
Univariate Analysis
(Cox Regression Model)
Multivariate Analysis
(Cox Regression Model) (6 Missing)
Median Overall
Survival (95% CI) Hazard Ratio (95% CI) P Value Hazard Ratio (95%CI) P Value
Age (year) o 65 (88) 24.1 (14.4, 33.9) 1.1 (0.8, 1.5) 0.750 1.0 (0.7, 1.4) 0.906
Z 65 (98) 26.9 (22.4, 31.4)
Sex Male (146) 26.3 (19.3, 33.4) 1.1 (0.7, 1.6) 0.725 1.1 (0.7, 1.6) 0.786
Female (40) 24.7 (12.0, 37.4)
Etiology Non-HBV (40) 25.5 (23.9, 27.0) 1.0 (0.7, 1.5) 0.885 0.9 (0.6, 1.5) 0.809
HBV (146) 26.9 (20.4, 33.4)
ECOG performance status 0 (179) 26.3 (21.2, 31.5) 1.7 (0.8, 4.0) 0.189 2.3 (0.9, 5.8) 0.086
Z 1( 7) 23.7 (4.1, 43.4)
Cirrhosis Absent (35) 28.7 (13.9, 43.5) 1.0 (0.7, 1.6) 0.891 1.5 (0.9, 2.4) 0.132
Present (151) 25.7 (20.1, 31.2)
Ascites Absent (162) 27.7 (23.5, 31.9) 1.7 (1.0, 2.7) 0.037 1.2 (0.7, 2.1) 0.510
Present (24) 15.2 (11.5, 19.0)
Prior treatments No/resection (148) 26.3 (21.5, 31.2) 1.1 (0.7, 1.6) 0.655 1.0 (0.6, 1.5) 0.832
Others (38) 24.1 (9.3, 39.0)
AFP level r 400 (131) 29.1 (23.0, 35.2) 1.2 (0.9, 1.7) 0.292 1.4 (0.9, 2.0) 0.124
4 400 (55) 18.9 (12.4, 25.4)
INR r 1.2 (129) 28.7 (20.8, 36.6) 1.5 (1.0, 2.1) 0.028 1.3 (0.8, 2.1) 0.215
4 1.2 (57) 19.7 (13.9, 25.5)
Albumin Grade 0 or 1 (169) 27.8 (23.1, 32.5) 2.5 (1.4, 4.2) 0.001 1.7 (0.9, 3.4) 0.101
Grade 2 (17) 9.2 (7.4, 11.0)
Total bilirubin Grade 0 or 1 (156) 27.8 (23.1, 32.6) 1.5 (1.0, 2.3) 0.067 1.4 (0.8, 2.5) 0.188
Grade 2 (30) 15.2 (9.1, 21.4)
Tumor number Solitary (143) 29.7 (21.9, 37.5) 1.7 (1.1, 2.4) 0.008 1.6 (1.0, 2.4) 0.040
Multifocal (43) 19.7 (14.0, 25.4)
Tumor size (cm) o 5 cm (104) 30.9 (23.4, 38.4) 1.5 (1.1, 2.1) 0.010 1.6 (1.0, 2.4) 0.040
Z 5 cm (82) 19.0 (13.5, 24.5)
Tumor burden (%) r 50 (163) 27.7 (22.5, 32.9) 1.6 (1.0, 2.6) 0.056 1.2 (0.7, 2.2) 0.533
4 50 (23) 20.4 (8.1, 32.7)
No. treatments 1 (54) 16.8 (9.4, 24.1) 0.6 (0.5, 0.9) 0.016 0.6 (0.4, 0.9) 0.008
4 1 (132) 29.1 (21.3, 36.9)
Tumor response at
6 mo (6 missing)
CR (88) 35.9 (24.2,47.5) 1.9 (1.3, 2.6) o 0.001 2.2 (1.5, 3.1) o 0.001
Others (92) 17.7 (9.2, 26.3)
Portal vein thrombosis Absent (177) 25.7 (20.4, 30.9) 1.2 (0.6, 2.5) 0.575 0.9 (0.4, 1.9) 0.718
Present (9) 33.5 (2.1, 64.8)
Child-Pugh class A (159) 28.7 (22.4, 35.0) 2.3 (1.5, 3.6) o 0.001
B (27) 13.4 (4.5, 22.3)
BCLC A (89) 37.1 (26.3, 47.9) 1.7 (1.2, 2.3) o 0.001
Others (97) 17.7 (12.4, 23.1)
UNOS T1 or T2 (91) 36.1 (23.9, 48.3) 1.6 (1.2, 2.3) 0.003
Others (95) 19.0 (12.7, 25.2)
Note–For Cox proportional hazards model, set the ﬁrst group as indicator for each category.
AFP ¼ α-fetoprotein; BCLC ¼ Barcelona Clinic Liver Cancer; CI ¼ conﬁdence interval; CR ¼ complete response; ECOG ¼ Eastern
Cooperative Oncology Group; HBV ¼ hepatitis B virus; INR ¼ international normalisation normalized ratio; UNOS ¼ United Network
for Organ Sharing; CR ¼ Complete response.
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Study of the Liver criteria was achieved in 69.1% of
lesions (159 of 230) and 48.9% (88 of 180) of patients at
6 months after TEA (Table 2). The relatively high CRrate associated with TEA suggested that this treatment is
effective in achieving local tumor control.
Based on the existing evidence, TEA might be superior in
achieving CR compared with transcatheter arterial
Figure 1. Kaplan-Meier curves of OS in subgroups classiﬁed according to the Child-Pugh (Child) cirrhosis classiﬁcation.
Figure 2. Kaplan-Meier curves of OS in subgroups classiﬁed according to the Barcelona Clinic Liver Cancer (BCLC) staging
classiﬁcation.
Volume 27 ’ Number 5 ’ May ’ 2016 645chemoembolization. However, when the OS of patients
treated with TEA (24.3 mo; 95% CI, 12.8–32.7) was
compared with OS of patients treated with transcatheterarterial chemoembolization (20.1 mo; 95% CI, 9.3–31.2),
the difference was not statistically signiﬁcant (P ¼ .358) (3).
The reason for nonsuperiority of TEA compared with
Figure 3. Kaplan-Meier curves of OS in subgroups classiﬁed according to the United Network for Organ Sharing (UNOS) staging classiﬁcation.
Figure 4. In a 51-year-old man with HBV-related HCC, a celiac axis arteriogram obtained with digital subtraction arteriography showed
a massive expansive hypervascular tumor in segment VII/VIII, which was supplied by a hypertrophied feeding artery (arrowheads) (a).
At the completion of LEM administration through a microcatheter that was introduced up to the tumor boundary, the tumor vasculature
and peritumoral portal venules were outlined with Lipiodol on radiography (b). Arteriogram obtained at 2 months showed a markedly
shrunken tumor with a well-deﬁned margin and Lipiodol retention. The arrowheads mark the position of the feeding artery which is now
not opaciﬁed (c). Digital subtraction arteriography performed at two different projections showed occlusion of the feeding artery
(arrowheads) and absence of intratumoral or peritumoral vascularity (d, e).
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Figure 5. In a 64-year-old man with HBV-related HCC, a proper hepatic artery arteriogram obtained with digital subtraction
arteriography showed a massive expansive hypervascular tumor in segment VI with a satellite lesion at its superolateral aspect,
which was supplied by a hypertrophied feeding artery (arrowheads) (a). A proper hepatic artery arteriogram obtained at the completion
of LEM administration showed occlusion of the feeding artery (arrowheads) and Lipiodol deposition within the tumor, its satellite lesion,
and peritumoral portal venules (b). A proper hepatic artery arteriogram obtained at 2 months showed a markedly shrunken tumor with
a well-deﬁned margin and Lipiodol retention and a patent, normal-sized feeding artery (arrowheads) (c). Digital subtraction
arteriography showed patency and normal size of the feeding arterial branch (arrowheads) and absence of intratumoral or peritumoral
vascularity (d).
Volume 27 ’ Number 5 ’ May ’ 2016 647transcatheter arterial chemoembolization in terms of OS is
likely due to the inability of TEA to control the occurrence
of new lesions arising from other parts of the liver or
outside the liver. Although the proportion of patients
with intralesional progression was low at 3 months and 6
months after TEA—5.4% (10 of 186) and 12.2% (22 of
180), respectively—the proportion of patients having
intrahepatic-extralesional progression or extrahepatic pro-
gression at 3 months and 6 months was substant-
ially higher—9.1% (17 of 186) and 26.7% (48 of 180),
respectively. The crucial factor for prolonging the OS of
patients after TEA is probably to control the intra-
hepatic-extralesional disease progression and extrahepaticdisease progression, not only to control the local tumor
with TEA.
In the present study, liver decompensation after TEA
was rare. Respiratory decompensation occurring after
TEA was reversible, nonfatal, and rare (1.6%; 3 of 186).
The operator could be alerted by the initial presenting
symptoms of cough or shortness of breath during the
procedure. Respiratory decompensation has also been
reported after transcatheter arterial chemoembolization
(10). Alcoholic intoxication was rare (0.5%; 1 of 186)
(Table 4). Other complications of transarterial treatment
that have been reported so far, including treatment-related
hepatitis in patients with HBV (11–13), liver abscess (14),
Table 3 . Tumor Response of Individual Tumors and Overall
Tumor Response of Individual Patients
Tumor Response n (%)
Tumor response of individual lesions
at 3 mo
n ¼ 246 lesions
Complete response 170 (69.1)
Partial response 50 (20.3)
Static response 16 (6.5)
Intralesional progression 10 (4.1)
Tumor response of individual lesions
at 6 mo
n ¼ 230 lesions
Complete response 159 (69.1)
Partial response 27 (11.7)
Static response 20 (8.7)
Intralesional progression 24 (10.4)
Overall tumor response of individual
patients at 3 mo
n ¼ 186 patients
Complete response 112 (60.2)
Partial response 37 (19.9)
Static response 13 (7)
Disease progression
Intralesional 10 (5.4)
Intrahepatic-extralesional or extrahepatic 17 (9.1)
Overall tumor response of individual
patients at 6 mo
n ¼ 180 patients
Complete response 88 (48.9)
Partial response 21 (11.7)
Static response 10 (5.6)
Disease progression
Intralesional 22 (12.2)
Intrahepatic-extralesional or extrahepatic 48 (26.7)
Deﬁnition of tumor response by European Association for the
Study of the Liver criteria:
1. Complete response ¼ absence of any enhancing tumor
tissue.
2. Partial response ¼ decrease in enhancing tumor tissue by
Z 50% in volume compared with baseline.
3. Static disease ¼ decrease in enhancing tumor tissue by
o 50% in volume compared with baseline.
Deﬁnition of disease progression:
1. Intralesional progression ¼ increase in enhancing tumor
tissue by 4 25% in volume compared with baseline in Z 1
lesions or recurrence of new foci after initial absence
of enhancing tissue within the previously treated tumor in
Z 1 lesions, or enlargement of previously shrunken enhan-
cing tissue within the previously treated tumor in Z 1
lesions.
2. Intrahepatic-extralesional progression ¼ occurrence of Z 1
new lesions in the liver parenchyma.
3. Extrahepatic progression ¼ occurrence of new tumor inva-
sion to venous structures, or occurrence of any extrahepatic
metastasis.
Table 4 . Treatment-Related Adverse Events
Adverse Events No. Patients (%)
Fever
Grade 1 87 (46.8)
Grade 2 41 (22)
Grade 3 0
Abdominal pain
Grade 1 87 (46.8)
Grade 2 27 (14.5)
Grade 3 3 (1.6)
Vomiting
Grade 1 16 (8.6)
Grade 2 7 (3.8)
Grade 3 0
Fatigue
Grade 1 26 (14)
Grade 2 21 (11.3)
Grade 3 0
Albumin Z grade 3
Baseline 0
2 wk 0
30 d 2 (1)
2 mo 2 (1)
Total bilirubin Z grade 3
Baseline 0
2 wk 5 (2.7)
30 d 7 (3.7)
2 mo 4 (2.1)
Alkaline phosphatase Z grade 3
Baseline 1 (0.5)
2 wk 0
30 d 0
2 mo 0
Alanine aminotransferase Z grade 3
Baseline 5 (2.7)
2 wk 2 (1)
30 d 5 (2.7)
2 mo 5 (2.7)
Transient respiratory decompensation 3 (1.6)
Transient confusion and drowsiness 1 (0.5)
Yu et al ’ JVIR648 ’ Transarterial Ethanol Ablation for Hepatocellular Carcinomaacute cholecystitis (14), gallbladder or bile duct infarction
(15,16), gastrointestinal bleeding and ulceration (14,17),
death within 30 days as a result of liver failure, cardiac
event, and infection (18), were not encountered with TEAin the present study. From the experience of intravascular
use of ethanol in embolization or sclerotherapy of vascular
anomalies, an ethanol dose of 1 mL/kg body weight per
treatment session was found to be safe (19); the dose limit
of 20 mL ethanol per treatment session in TEA should
have a wide safety margin. Known complications of
intravascular ethanol administration, such as rhabdom-
yolysis (19), cardiopulmonary collapse, cardiac arrhythmia,
and hemoglobinuria secondary to hemolysis (19,20), did
not occur after TEA in this study.
For a comprehensive evaluation of the treatment effect
of TEA in different subgroups of patients with unresect-
able HCC, we deliberately included patients who were not
treatment-naïve. We believe such evaluation is important
because tumor recurrence is common in patients with
Volume 27 ’ Number 5 ’ May ’ 2016 649HCC after locoregional therapy or liver resection, and
transarterial treatment is often required in the clinical
management of these patients. The difference in median
OS between patients who were not treatment-naïve and
patients who were treatment-naïve was not statistically
signiﬁcant (22.7 mo [95% CI, 13.9–31.6] vs 28.7 mo [95%
CI, 23–34.4], P ¼ .34).
This study has some limitations. First, the study
was limited by its slow and long span of case accrual,
although the treatment procedure and study methodology
remained unchanged throughout. Second, although the
inclusion of patients with different tumor stages and
liver function status could be considered a limitation, it
provided an opportunity for comprehensive analysis of
the tumor and liver factors affecting treatment outcome.
To achieve this purpose, we included the entire patient
cohort treated with TEA in our institution, including data
of patients that had been reported previously (1–3). Third,
the use of CT instead of MR imaging was less desirable in
the assessment of tumor response. Although the risk of
underdiagnosing intralesional disease progression or
residue with the use of CT was minimal because these
conditions were evaluated in retrospect at the time they
were ﬁrst detected, there could have been a delay in
diagnosis and treatment of the tumor, and that might
have affected the OS. Finally, for patients with HBV,
serum HBV DNA level was not checked, so the effect of
TEA on HBV reactivation was not evaluated.
In conclusion, TEA appears to be safe and effective for
local tumor control in patients with unresectable HCC.ACKNOWLEDGMENTS
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